Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.

Date publication

janvier 2023

Journal

Breast cancer (Tokyo, Japan)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe , Dr DESMOULINS Isabelle , Dr EBERST Lauriane

Tous les auteurs :
Collet L, Eberst L, Ludovic G, Debled M, Hrab L, Mouret-Reynier MA, Desmoulins I, Goncalves A, Campone M, Ferrero JM, Brain E, Uwer L, Eymard JC, Dieras V, Simon G, Leheurteur M, Dalenc F, Vanlemmens L, Darlix A, Arnedos M, Bachelot T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36630013

Résumé

More than 10% of HER2-positive metastatic breast cancer (mBC) will develop Central Nervous System (CNS) metastases as first and isolated site of relapse on trastuzumab and pertuzumab first-line therapy. However, few clinical data are available to guide the best strategy in this setting.

Mots clés

Brain metastases, Breast neoplasms, Pertuzumab, Trastuzumab, Tyrosine kinase-type cell surface receptor HER2

Référence

Breast Cancer. 2023 01 11;: